Pharmanovia unveils results in new Sustainability Report and pledges commitment to new environmental and sustainability targets
Basildon, UK: Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced increased targets to divert 40% of its air shipments to sea in 2023, and 75% by the end of 2028.
Pharmanovia has made the pledge as it revealed the significant progress made towards achieving its ambitious science-backed ESG initiatives in its new Sustainability Report. Its industry-leading air-to-sea pilot scheme, which focused on its Spain-to-Australia freight route, cut an estimated 470,000kg in potential CO2 emissions in 2022 – reducing Scope 3 upstream transport emissions by 18%.
This initiative demonstrates Pharmanovia’s role as an industry leader on carbon reduction and follows a recent report which stated just 16 of 500 pharmaceutical companies measured their entire Scope 3 emissions.
Additional highlights from the report include:
Other initiatives include a 2030 target being established for Pharmanovia’s transition to an electric hybrid vehicle fleet, while technology is also being embraced to strengthen the company’s already robust Supply Chain Policy. A digital due diligence tool has been piloted and will be rolled out further in 2023 to provide continuous and automated monitoring of all partnerships, including their own ESG activities.
The company has set itself a goal of net-zero greenhouse gas (GHG) emissions by 2030, which is aligned with science-based targets that support the United Nations Climate Change Paris Agreement to limit global warming to well below 2°C above pre-industrial levels and to pursue efforts to limit warming to 1.5°C. Pharmanovia’s Net-Zero goals have been validated by the Science-Based Target Initiative (SBTi).
James Burt, CEO, Pharmanovia said: “We are proud of the progress made in the last year despite headwinds faced due to global challenges and geopolitical complexity. Today’s set of environmental targets, including our landmark pledge to transition from air freight to sea freight, demonstrate our commitment to establishing novel routes for the industry to reach net zero. The innovative pilot not only delivered benefits in terms of carbon, but in waste and cost reduction, too.
“Our purpose is to improve the lives of patients globally, which is why setting meaningful targets to reduce our environmental impact is critical, to build a sustainable future for patients and the sector. We look forward to working with our partners within our supply chain to ensure we are all held to the most rigorous of environmental standards.”
Neeshe Williams, Head of ESG and General Counsel, Pharmanovia said: “A report from PwC’s Health Research Institute highlighted that just 12% of ESG targets set by pharmaceutical companies relate to environmental initiatives, showing an increased focus is needed. At Pharmanovia, we believe deeply in addressing the climate impact of our own business as well as the partners we work with. All employees have been assigned individual ESG targets as part of their performance review, to reinforce ESG is something we do, not just talk about, and encourage them to apply a sustainable lens to the work they do.”
Notes to editors
Results captured during the calendar year, 1 January to 31 December 2022
Scope 1 emissions
Scope 1 covers emissions from sources that an organisation owns or controls directly.
Scope 2 are emissions that a company causes indirectly when the energy it purchases and uses is produced.
Scope 3 encompasses emissions that are not produced by the company itself, and not the result of activities from assets owned or controlled by them, but by those that it’s indirectly responsible for, up and down its value chain.
For further information, please contact:
Alison Dyson, Director of Communications, Pharmanovia
07442 256310/ Alison.email@example.com
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by rediscovering, repurposing or re-engineering established medicines to improve patient outcomes and experiences as well as identifying new chemical entities that complement our existing portfolio to address unmet need.